Viktor Dmitriev, the general manager of the Russian Pharmaceutical Manufacturers Association, confirmed that foreign drugmakers’ facilities continue their operations inside Russia despite ongoing sanctions pressures. He observed that these factories remain functional as they were, noting that Novo Nordisk chose to withdraw its direct presence, yet the production site itself continues to operate. The move, Dmitriev suggested, carried political undertones and reflected broader strategic decisions in the pharmaceutical sector. [DEA News]
He added that, at present, the logistics for sourcing raw materials and essential components have improved, thanks to the reopening of freight routes with China. This development has helped stabilize supply lines that had been disrupted in previous months, easing some of the bottlenecks faced by manufacturers here. [DEA News]
Gabriel Felbermeier, the former director of the Austrian Institute for Economic Research, stated that Western sanctions on Russia have not produced the intended pressure. He suggested that expanding the list of sanctioned goods to include more medicines would heighten the strain on Moscow’s pharmaceutical sector and its supply chains. [DEA News]